Detalles de la búsqueda
1.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer
; 127(5): 836-843, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35637412
2.
Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO).
Cancers (Basel)
; 14(6)2022 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35326695
3.
Response and Disease Dynamics in Untreated Metastatic Colorectal Cancer With Bevacizumab-Based Sequential vs. Combination Chemotherapy-Analysis of the Phase 3 XELAVIRI Trial.
Front Oncol
; 12: 751453, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35251955
4.
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
Eur J Cancer
; 147: 128-139, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33647548
5.
Impact of age on efficacy and early mortality of initial sequential treatment versus upfront combination chemotherapy in patients with metastatic colorectal cancer: a subgroup analysis of a phase III trial (AIO KRK0110, XELAVIRI study).
Eur J Cancer
; 137: 81-92, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32750502
6.
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
J Clin Oncol
; 37(1): 22-32, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30388045
Resultados
1 -
6
de 6
1
Próxima >
>>